An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated July 17, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on Rapamycin; the papers are listed at the end. Research summary, not a recommendation.
What it is
Rapamycin, also called sirolimus, is a large ring-shaped molecule (a macrolide) made by the soil bacterium Streptomyces hygroscopicus, first isolated in the early 1970s from a soil sample collected on Easter Island (Rapa Nui), which gave it its name. It is not a peptide. It is an FDA-approved prescription drug, first approved in 1999 to prevent rejection of kidney transplants and later for the rare lung disease lymphangioleiomyomatosis (LAM); it is also used in drug-coated heart stents. Its use to slow aging is off-label and experimental.
How it works
Rapamycin binds a small protein inside cells called FKBP12, and the pair then blocks mTOR complex 1 (mTORC1), a master switch that senses nutrients and growth signals. When mTORC1 is active, cells build protein and grow; when it is blocked, growth slows and the cell's recycling system (autophagy) is switched on. Blocking mTORC1 in immune cells dampens T-cell proliferation, which is why it prevents transplant rejection. With long, continuous exposure it also partly blocks a second complex, mTORC2, which is linked to its effects on blood sugar and fats. Lowering mTOR activity extends lifespan in yeast, worms, flies and mice, which is the basis of the aging research.
Lymphangioleiomyomatosis, a rare progressive lung disease (randomized trial; approved use)
Immune aging and vaccine response in older adults (randomized trials of rapamycin-class drugs)
Healthspan measures in healthy older adults (randomized trial)
Lifespan extension in mice (animal studies)
Strength of the evidence
Approved drugSirolimus is FDA-approved for transplant rejection and lymphangioleiomyomatosis; for aging, the human evidence is small short-term trials and an observational survey of off-label users.
What the literature reports on safety
As an approved immunosuppressant, the sirolimus label carries a boxed warning about increased risk of serious infections and of lymphoma and other cancers, and lists mouth ulcers, raised cholesterol and triglycerides, raised blood sugar, impaired wound healing, swelling and lung inflammation among its effects. A 2024 systematic review found no serious adverse events attributed to rapamycin in healthy people in short aging studies, but more infections and higher cholesterol and triglycerides in people with age-related diseases. Long-term safety of intermittent use for aging is unknown.
Review · Lee DJW, Hodzic Kuerec A, Maier AB · The Lancet. Healthy Longevity (2024) · PMID 38310895
A systematic review of human studies of rapamycin and related drugs for aging found some benefits on immune, cardiovascular and skin measures, no serious adverse events in healthy people, and more infections and lipid rises in people with age-related diseases.
Randomized trial · McCormack FX, Inoue Y, et al. · The New England Journal of Medicine (2011) · PMID 21410393
In the MILES trial, sirolimus stabilized lung function and improved quality of life in lymphangioleiomyomatosis compared with placebo, with decline resuming after it was stopped.
Randomized trial · Mannick JB, Del Giudice G, et al. · Science Translational Medicine (2014) · PMID 25540326
In older adults, the rapamycin derivative everolimus improved the response to influenza vaccination and reduced the share of exhausted (PD-1-positive) T cells.
Randomized trial · Moel M, Harinath G, et al. · Aging (2025) · PMID 40188830
In the PEARL trial of healthy older adults, intermittent low-dose rapamycin for 48 weeks had adverse events similar to placebo and did not change visceral fat, the main outcome; lean mass and pain improved in women in one dose group.
Cohort study · Kaeberlein TL, Green AS, et al. · GeroScience (2023) · PMID 37191826
A survey of 333 adults using rapamycin off-label for healthspan, compared with 172 non-users, offered initial evidence that it could be used safely in healthy adults, with self-reported data only.
Animal study · Harrison DE, Strong R, et al. · Nature (2009) · PMID 19587680
In genetically diverse mice, rapamycin started late in life extended both median and maximal lifespan in males and females.
Sources checked: PubMed/PMC (E-utilities esearch, esummary and abstracts on every PMID), FDA label (Rapamune) for regulatory status and boxed warning, written 2026-11-06.
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about Rapamycin? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.